🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Interesting efficacy signal for bladder preservation (TMT) + nivolumab. Increased #bladdercancer free survival & OS va TMT No new safety issue. Additional data expected from GETUG Bladder Sparing study. Larger trials needed. #ESMO2024

Excellent opportunity for a medical oncologist McGill University Centre universitaire de santé McGill to join a collaborative and enriched academic environment in the wonderful city of #montreal. Please apply or RT

Joseph Liao, MD presenting at #IBCN24 IBCN in Bern 🇨🇭 augmented cystoscopy AI. Phenomenal value added technology so key to diagnose and manage bladder cancer patients. Optimize, generalize/simplify, and automate! IBCG World Bladder Cancer Patient Coalition Bladder Cancer Advocacy Network UTMBUrology

Jacqueline Fontugne presenting at #IBCN24 IBCN AI subtype prediction model in bladder cancer. AI value added tools to generalize and provide high quality reliability across the globe! More to come and exciting collaborative work.🔥🧐Bladder Cancer Advocacy Network UroToday.com UTMBUrology Valar Labs

Benefit of WP-RT for MIBC: 🇨🇦IPTW Analysis UroToday.com #IBCN2024 IBCN Gautier Marcq 🇨🇭n=599, 369 WP-RT vs 220 BO-RT 🇨🇭~3 mo post-RT: 407 pts (76%) had CR 🇨🇭OR for CR post-RT: hydro - OR 0.45, 95% CI 0.28-0.71 WP-RT vs BO-RT: 🇨🇭CR post-RT: OR 1.14, 95% CI 0.76-1.72 🇨🇭CSS: HR

In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results: nej.md/4dBI8UN

Just out. Ipi/nivo didn’t hit OS in cisplatin ineligible or PD-L1 +ve in 1st line UC in CM901. Surprising? Durva/treme (also -ve) had activity, especially in PD-L1 +ves(HR 0.74, CI 0.6-0.9-not stat tested). Different PD-L1 biomarkers used. Data awaited !! news.bms.com/news/corporate…

#LEGEND trial investigates EG-70 in #BladderCancer patients. 💡 Exciting insights from Gautier Marcq Université de Lille and Zach Klaassen Georgia Cancer Center explore detalimogene voraplasmid (EG-70) for BCG-unresponsive #NMIBC with carcinoma in situ. This phase 1/2 study, enrolling patients

Deeply honored to join the #IBCG. Earger to start working with such an esteemed group of colleagues 👩‍🏫👨‍🏫 committed to improving #urothelialcancer care. Our patients deserved it. IBCG CHU de Lille Université de Lille World Bladder Cancer Patient Coalition Cancer Vessie France Wes Kassouf

Only 25 % of our 🇫🇷 residents are interested in #Academics. Fantastic talk from Denis Séguier. Nothing more rewarding to see your #trainees shinning on the stage. #BAU2024 Association Française d'Urologie - AFU

Big news👋. A positive R3 trial for PD-1 in NMIBC! The CREST trial evaluated sasanlimab (PD-1i)+BCG vs Standard BCG (induction and maintenance) in BCG-naïve, high-risk NMIBC.The study met its primary endpoint of EFS with ‘clinically meaningful’ results. pfizer.com/news/press-rel…

Study finds whole pelvis radiotherapy superior to bladder-only in #MIBC treatment. Gautier Marcq Université de Lille joins Leslie Ballas Cedars-Sinai to discuss a Journal of Clinical Oncology publication comparing whole pelvis vs bladder-only radiotherapy in muscle-invasive bladder cancer. #FullVideo on